FY2017 Earnings Estimate for Corvus Pharmaceuticals, Inc. Issued By Cantor Fitzgerald (CRVS)

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Research analysts at Cantor Fitzgerald cut their FY2017 earnings estimates for Corvus Pharmaceuticals in a research report issued to clients and investors on Tuesday. Cantor Fitzgerald analyst M. Goldstein now anticipates that the company will post earnings of ($2.96) per share for the year, down from their prior estimate of ($2.60). Cantor Fitzgerald also issued estimates for Corvus Pharmaceuticals’ FY2018 earnings at ($3.31) EPS.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its quarterly earnings results on Thursday, August 3rd. The company reported ($0.73) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.76) by $0.03.

TRADEMARK VIOLATION NOTICE: “FY2017 Earnings Estimate for Corvus Pharmaceuticals, Inc. Issued By Cantor Fitzgerald (CRVS)” was reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/2797943/fy2017-earnings-estimate-for-corvus-pharmaceuticals-inc-issued-by-cantor-fitzgerald-crvs.html.

Several other research firms have also weighed in on CRVS. Credit Suisse Group reduced their target price on Corvus Pharmaceuticals from $26.00 to $17.00 and set an “outperform” rating for the company in a report on Tuesday, July 4th. Cowen and Company restated an “outperform” rating on shares of Corvus Pharmaceuticals in a report on Tuesday, July 4th. Zacks Investment Research upgraded Corvus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a report on Monday, July 17th. Finally, Wedbush began coverage on Corvus Pharmaceuticals in a report on Wednesday, August 2nd. They issued an “outperform” rating and a $26.00 target price for the company. Five investment analysts have rated the stock with a buy rating, Corvus Pharmaceuticals currently has an average rating of “Buy” and an average price target of $20.50.

Corvus Pharmaceuticals (NASDAQ CRVS) opened at 11.30 on Thursday. The company has a 50-day moving average of $12.12 and a 200 day moving average of $12.86. The stock’s market cap is $236.55 million. Corvus Pharmaceuticals has a 12-month low of $8.27 and a 12-month high of $22.14.

In related news, insider Richard A. Md Miller bought 25,000 shares of Corvus Pharmaceuticals stock in a transaction that occurred on Tuesday, June 13th. The stock was purchased at an average cost of $9.88 per share, for a total transaction of $247,000.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Holdings A/S Novo bought 20,000 shares of Corvus Pharmaceuticals stock in a transaction that occurred on Friday, June 23rd. The stock was bought at an average price of $10.95 per share, with a total value of $219,000.00. Following the completion of the acquisition, the insider now owns 3,244,046 shares in the company, valued at approximately $35,522,303.70. The disclosure for this purchase can be found here.

A number of large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp increased its position in shares of Corvus Pharmaceuticals by 81.6% in the second quarter. Bank of New York Mellon Corp now owns 28,978 shares of the company’s stock valued at $351,000 after buying an additional 13,023 shares in the last quarter. Schwab Charles Investment Management Inc. acquired a new position in shares of Corvus Pharmaceuticals during the second quarter valued at approximately $212,000. Russell Investments Group Ltd. increased its position in shares of Corvus Pharmaceuticals by 29.3% in the second quarter. Russell Investments Group Ltd. now owns 9,286 shares of the company’s stock valued at $112,000 after buying an additional 2,105 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Corvus Pharmaceuticals during the first quarter valued at approximately $8,480,000. Finally, Endurant Capital Management LP acquired a new position in shares of Corvus Pharmaceuticals during the first quarter valued at approximately $282,000. Hedge funds and other institutional investors own 82.66% of the company’s stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.

Earnings History and Estimates for Corvus Pharmaceuticals (NASDAQ:CRVS)

Receive News & Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.